Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Odense University Hospital
Age
18–81
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ST segment elevation acute myocardial infarction
20% \< angiographic diameter stenosis \< 50% on a not previously revascularized native coronary artery
Statin naïve
You may not be if
Pharmacologic lipid lowering treatment before index hospitalization
Atrial fibrillation, not well rate-controlled
Ventricle frequency variation with more than a factor 2 over 1 minute
Unconscious patients
Total cholesterol \> 7.0 mmol/l
History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins) including rosuvastatin
Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have a positive serum pregnancy test (a serum-human chorionic gonadotrophin \[Beta-HCG\] analysis)
History of malignancy (unless a documented disease free period exceeding 5-years is present) with the exception of basal cell or squamous cell carcinoma of the skin, or in the case of a study designed to investigate antineoplastic properties of rosuvastatin. Women with a history of cervical dysplasia would be permitted to enter the study provided they had 3 consecutive clear Papanicolaou (Pap) smears
Uncontrolled hypothyroidism (TSH \> 1.5xULN)
Abnormal LFT's
History of alcohol or drug abuse within the last 5 years (this may affect compliance)
Current active liver disease (ALT/SGPT \>2xULN or severe hepatic impairment (to protect patient safety as directed on the labels of currently approved statins)
Unexplained creatine kinase (CK \> 3xULN) (To protect patient safety) (will be increased at baseline because of acute ST segment elevation myocardial infarction a few days before enrolment)
Serum creatinine \>176mmol/L (2.0mg/dL) (unless the protocol specifically aims to investigate a chronic renal disease population)
Participation in another investigational drug study less than 4 weeks before enrolment in the study, or according to subjects local ethics committee requirements where a larger period is stipulated (to avoid potential misinterpretation of overlapping adverse events)